News Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 23:00:00 18/06/2024 BST			5-day change	1st Jan Change
19.69 ^CAD	+0.87%		+1.13%	-6.90%

04:54pm	J&J: launches open, secure digital ecosystem	CF
03:46pm	J&J: promising results in Crohn's disease	CF

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

J&J: launches open, secure digital ecosystem	03:54pm	CF
J&J: promising results in Crohn's disease	02:46pm	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	02:38pm	MT
Johnson & Johnson Sees Positive Trial Results for Tremfya	01:42pm	DJ
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	01:01pm	PR
Johnson & Johnson - Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	06-18	AQ
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	06-17	BU
J&J commits five-year investment in Italian medicine manufacturing	06-17	AQ
Johnson & Johnson - Late-breaking results show nipocalimab significantly improves Sjogren's disease activity in a Phase 2 study	06-17	AQ
Johnson & Johnson - TALVEY demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma	06-17	AQ
J&J: FDA application in lung cancer	06-17	CF
Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	06-17	MT
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	06-17	CI
J&J: positive results in Sjögren's disease	06-17	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	06-17	MT
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	06-15	PR
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15	CI
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	06-14	PU
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
J&J: encouraging trial in relapsing multiple myeloma	06-14	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm